FORWARD GLOBAL
FORWARD GLOBAL filed a Q2 report for QUOIN PHARMACEUTICALS, INC. on July 21, 2025, reporting $20,000 in lobbying income.
Lobbying for QUOIN PHARMACEUTICALS, INC. · Development and commercialization of therapeutic drug products that treat rare diseases.
Lobbying for continued funding from the government for rare disease research and development, including through the Rare Pediatric Disease Designation and Priority Review Voucher Programs; advocating for greater awareness about the rare disease community for doctors via the Give Kids a Chance Act.
Lobbying for continued funding from the government for rare disease research and development, including through the Rare Pediatric Disease Designation and Priority Review Voucher Programs; advocating for greater awareness about the rare disease community for doctors via the Give Kids a Chance Act.
Lobbying for continued funding from the government for rare disease research and development, including through the Rare Pediatric Disease Designation and Priority Review Voucher Programs; advocating for greater awareness about the rare disease community for doctors via the Give Kids a Chance Act.